Should a matched sibling donor still be considered the primary option for allogeneic hematopoietic cell transplantation in patients over 50 years of age with myelodysplastic syndrome?

Takaaki Konuma, Hidehiro Itonaga, Ken Ishiyama, Noriko Doki, Naoyuki Uchida, Masashi Sawa, Yuta Katayama, Masatsugu Tanaka, Yasunori Ueda, Makoto Onizuka, Shigesaburo Miyakoshi, Yukiyasu Ozawa, Takahiro Fukuda, Ken-ichi Matsuoka, Junji Tanaka, Takafumi Kimura, Tatsuo Ichinohe, Yoshiko Atsuta

doi:10.1038/s41409-023-01997-3

<jats:title>Abstract</jats:title><jats:p>Human leukocyte antigen (HLA)-matched sibling donors (MSDs) are the preferred choice for allogeneic hematopoietic cell transplantation (HCT). However, as myelodysplastic syndrome (MDS) is most frequently diagnosed in the elderly, MSDs are also likely to be of advanced age. It is unclear whether an MSD should be considered the primary choice for allogeneic HCT in elderly patients with MDS. We retrospectively compared survival and other outcomes in 1787 patients with MDS over 50 years of age and receiving allogeneic HCT between 2014 and 2020, using either MSD (<jats:italic>n</jats:italic> = 214), 8/8 allele-matched unrelated donor (MUD) (<jats:italic>n</jats:italic> = 562), 7/8 allele-MUD (<jats:italic>n</jats:italic> = 334), or unrelated cord blood (UCB) (<jats:italic>n</jats:italic> = 677) in Japan. In multivariate analysis, compared to MSD transplants, the risk of relapse was significantly lower following 8/8MUD transplants (hazard ratio [HR], 0.74; <jats:italic>P</jats:italic> = 0.047), whereas non-relapse mortality was significantly higher following UCB transplants (HR, 1.43; <jats:italic>P</jats:italic> = 0.041). However, donor type did not determine overall survival, disease-free survival, or graft-versus-host disease (GVHD)-free, relapse-free survival, but chronic GVHD-free, relapse-free survival was better after UCB (HR, 0.80; <jats:italic>P</jats:italic> = 0.025) and 8/8MUD (HR, 0.81; <jats:italic>P</jats:italic> = 0.032) compared to MSD transplants. Our study demonstrated that MSDs are not superior to alternative HCT methods, such as 8/8MUD, 7/8MUD, or UCB, in this population.</jats:p>

Should a matched sibling donor still be considered the primary option for allogeneic hematopoietic cell transplantation in patients over 50 years of age with myelodysplastic syndrome?

Search this article

Description

Journal

Citations (2)*help

References(44)*help

Related Projects

Keywords

Details 詳細情報について

Export

Report a problem